Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX + PD-1 inhibitor + bevacizumab biosimilar versus XELOX + bevacizumab biosimilar in first-line RAS-mutant pMMR/MSS advanced colorectal cancer
ChiCTR2100048743Phase 2Not yet recruiting
- Sponsor
- First Medical Center of Chinese PLA General Hospital
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, capecitabine and oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by First Medical Center of Chinese PLA General Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
bevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100048743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048743.